Tislelizumab Combined With Chemotherapy and Relayed Radiotherapy in First-line Treatment of ES-SCLC
Clinical trial NCT06838208 · RECRUITING
Trial details
- NCT number
- NCT06838208
- Sponsor
- Anhui Provincial Cancer Hospital
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-02-25
- Primary completion
- 2027-03-01
- Enrollment
- 56
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.